GlassScriptPhysician profile
Sheela L Gade
NPI 1114143757
$3,514.57
in general payments reported to CMS, 2019-2025
24 companies · $881 in 2025
The $881 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,493 · 2020: $232 · 2021: $17.76 · 2023: $608 · 2024: $283 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,772.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $401.51 | 2019-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $280.72 | 2019-2024 | Rexulti |
| Abbvie INC. | $273.99 | 2021-2025 | |
| Tris Pharma INC | $264.99 | 2019-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $249.70 | 2019-2023 | Trintellix |
| Allergan, INC. | $206.30 | 2019 | |
| Alkermes, INC. | $200.39 | 2019-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $181.18 | 2019-2020 | |
| Bausch Health US, LLC | $177.83 | 2023-2025 | Aplenzin |
| Axsome Therapeutics, INC. | $177.66 | 2023-2025 | Auvelity, Sunosi |
| E.R. Squibb & Sons, L.L.C. | $150.57 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $145.22 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $143.38 | 2019-2025 | Uzedy, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $100.08 | 2019-2024 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $89.46 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.45 | 2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $77.34 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $76.25 | 2024-2025 | Qelbree |
| Neos Therapeutics, LP | $66.89 | 2019-2020 | |
| Corium, LLC | $51.96 | 2024-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $43.92 | 2019-2025 | |
| Almatica Pharma LLC | $41.05 | 2024-2025 | Loreev Xr |
| Luye Pharma (USA) LTD. | $14.12 | 2025 | Erzofri Extended-Release |
| Merck Sharp & Dohme LLC | $13.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheela Gade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.